GIS Spinout PathGen Dx to Seek FDA Clearance for Chip-Based Test that Can Detect 70K Pathogens | GenomeWeb

SINGAPORE— Just over a year after beginning operations, PathGen Dx is moving forward with the commercialization of an assay for infectious disease testing.

The assay, which combines a single PCR amplification with an approximately 170,000-probe array, can identify some 70,000 viral and bacterial pathogens, including many that cannot be detected using other commercial multiplexed pathogen-detection assays, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.